Product Description
FXIa inhibitor, being developed for the treatment of thrombosis (Sourced from: https://www.ono-pharma.com/sites/default/files/en/ir/library/financial_results/fi1029.pdf)
Mechanisms of Action: FXIa Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ONO Pharm
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Venous Thromboembolism
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
jRCT2071220101 |
jRCT2071220101 | P1 |
Active, not recruiting |
Venous Thromboembolism |
2024-03-31 |
Recent News Events
Date |
Type |
Title |
|---|